Immunitybio is trading 5.05% up at $10.29 alongside the FDA’s October 14, 2026 expansion of Anktiva’s approval. - The significant company-specific milestone covers adults with BCG-unresponsive, high-grade papillary-only bladder cancer receiving BCG. - News coverage confirms the expanded indication but does not explicitly link it to the precise intraday gain. - Hotter-than-expected inflation pressures broader markets, and supplied sector context also reports biotech weakness; these headwinds appear less explanatory than the same-day FDA decision.